Overview

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A randomized active-controlled multi-site double-masked study to evaluate the safety and tolerability of 2 concentrations of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma
Phase:
Phase 2
Details
Lead Sponsor:
Qlaris Bio, Inc.